BRAF and cancer: BRAF inhibitors such as sorafenib also bind to the kinase domain of BRAF (PDB ID:1UWH) and if these drugs also act as BRAF inhibitors or disrupt the BRAF-RAF1 protein interface, they can be potential anti-cancer drugs.